|
 |
FuzeonThis page contains recent news articles, when available, and an overview of Fuzeon but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Fuzeon (when available) Not Available For treatment of HIV AIDS Mechanism Of Action: Not Available News Articles on Enfuvirtide Trimeris Shares Fall As Arigene Ends Offer - Dec 29, 2009 Trimeris said it plans to focus on its Fuzeon drug, the first in a new class of anti-HIV drugs called fusion inhibitors. Arigene, though its RTM Acquisition ... Wall Street Journal Pfizer Discontinues Cancer Drug: Biotech's Recently Missed Targets - Jan 4, 2010 Trimeris intends to continue to actively manage its operations so as to maximize cash flow attributable to its commercial product Fuzeon. Seeking Alpha (blog) Coinstar, Cosan, H&R Block, YRC Worldwide: US Equity Movers - Dec 29, 2009 The maker of the HIV drug Fuzeon said Arigene Co. (067850 KS) terminated its offer to buy the company after failing to obtain “sufficientâ€? funding. ... BusinessWeek Slide in energy breaks six-day winning streak - Dec 29, 2009 Shares in Trimeris, which makes the HIV drug Fuzeon, plunged 16.7 per cent to $2.65. AspenBio Pharma rallied 15.4 per cent to $1.80 after the biotechnology ... Financial Times Arigene终æ¢å…¬å¼€æ”¶è´Trimeris股票 - Dec 29, 2009 Trimeris将继ç»ç§¯æž?管ç?†å…¶äº‹ä¸šï¼Œä»¥æ‰©å¤§å•†ä¸šäº§å“?FUZEON(R)现金æµ?é‡?。 å…?è´£å£°æ˜Žï¼šæœ¬æ–‡ä»…ä»£è¡¨ä½œè€…ä¸ªäººè§‚ç‚¹ï¼Œä¸Žå‡¤å‡°ç½‘æ— å…³ã€‚å…¶åŽŸåˆ›æ€§ä»¥å?Šæ–‡ä¸é™ˆè¿°æ–‡å—和内容未ç»?本站è¯?实， ... 凤凰网 СШÐ?: Ñ?мешаннаÑ? динамика на фоне Ñ?нижениÑ? котировок нефтÑ?ников и ... - Dec 29, 2009 Производитель препарата Fuzeon, иÑ?пользуемого длÑ? лечениÑ? больных Ñ? вируÑ?ом иммунодефицита, Ñ?ообщил, что Arigene не удалоÑ?ÑŒ найти Ñ?редÑ?тва на покупку ... Финам.RU Trimeris profit sliced in half - Nov 13, 2009 The drop was due largely to declining sales of HIV treatment Fuzeon, which Trimeris developed and Roche Laboratories Inc. distributes. ... Triangle Business Journal South Korean firm formally launches buyout of Trimeris - Oct 19, 2009 The company developed the HIV drug Fuzeon, which is manufactured and sold internationally by Roche. Arigene is making the buy through its subsidiary RTM ... Local Tech Wire WND People - Oct 30, 2009 Fuzeon, the AIDS drug of last resort that has been successful in treating patients who no longer benefit from other drugs, for example, has been denied to ... WND.com Arigene Co., Ltd. Commences Tender Offer to Acquire All Outstanding Shares of ... - Oct 19, 2009 FUZEON, approved in the US, Canada and European Union, is the first in a new class of anti-HIV drugs called fusion inhibitors. For more information about ... Reuters Trimeris Sued Ahead of Deal - Oct 31, 2009 Earlier this month, a South Korean company launched a tender offer to acquire Trimeris, the developer of the AIDS drug Fuzeon, for $3.60 a share. ... American Chronicle GOP's Coburn Seeks Gays to Stop Obamacare - Nov 2, 2009 Fuzeon, a drug of last resort, has been denied to program participants in Washington, DC, they said. The pair blamed bureaucratic inefficiencies for the ... NewsMax.com 아리진, 600ì–µ ìœ ì¦? 실패..ç¾Žì œì•½ì‚¬ ì?¸ìˆ˜ `ë‚œí•`(ìƒ?ë³´) - Nov 11, 2009 ...트ë?¼ì?´ë¨¸ë¦¬ìŠ¤ëŠ” ê¸€ë¡œë²Œì œì•½ì‚¬ 로슈ì—? ì—?ì?´ì¦ˆ ì¹˜ë£Œì œ `í“¨ì œì˜¨(Fuzeon)`ì?˜ 특허 ë?¼ì?´ì„ 스를 ì œê³µí•˜ëŠ” ë°”ì?´ì˜¤ê¸°ì—…ì?´ë‹¤. 아리진ì?€ 트ë?¼ì?´ë¨¸ë¦¬ìŠ¤ ì?¸ìˆ˜ ì?´í›„ ì—?ì?´ì¦ˆ ì¹˜ë£Œì‹ ì•½ ... 이데일리 ì—?ì?´ì¦ˆ ì¹˜ë£Œì œ, 무엇보다 시급한 ê³¼ì œ - Nov 11, 2009 2003ë…„ ì?´í›„ì—? 기존ì?˜ ì—?ì?´ì¦ˆ ì¹˜ë£Œì œë“¤ê³¼ 차별화ë?˜ëŠ” 새로운 ì¹˜ë£Œì œë¡œ ê°?ì—¼ 1단계를 ì €í•´í•˜ëŠ” í‘¸ì œì˜¨(Fuzeon, 로슈사) ë°? 셀센트리(Selzentry, í™”ì?´ìž?), ê·¸ë¦¬ê³ ê°?ì—¼ 3 ... 파이낸스 투데이 아리진,美, 트ë?¼ì?´ë¨¸ë¦¬ìŠ¤ì™€ êµë‚´ì—?ì„œ ì—?ì?´ì¦ˆ ì¹˜ë£Œì œ 연구 - Oct 20, 2009 ...트ë?¼ì?´ë¨¸ë¦¬ìŠ¤ì—?ì„œ 개발한 FUZEONì?€ í• HIV ì•½ì œ 등급ì—? 있어서 ìœµí•©ì–µì œì œë¡œëŠ” 최초로 2003ë…„ 승ì?¸ì?„ 받았다. ì?´ ì•½ì œì?˜ 효능 ê¸°ì œëŠ” ì?´ì „ì?˜ í• HIV ì•½ì œì™€ëŠ” ì™„ì „ížˆ ... 파이낸스 투데이 ì—?ì?´ì¦ˆ 치료, 어떻게 가능한가? - Oct 25, 2009 ...inhibition)ë?¼ê³ 하는 ê¸°ìˆ ì?„ 탑재한 'Enfuvirtide' 성분ì?˜ ì¹˜ë£Œì œê°€ 2003ë…„ ë¯¸êµ FDAì?˜ 승ì?¸ì?„ 받아 íŒ?매 중ì?´ë©° 가장 대표ì ?ì?¸ ì œí’ˆì?´ í“¨ì œì˜¨(Fuzeon)ì?´ë‹¤. ... 파이낸스 투데이 Trimeris Cuts Fuzeon Sales View - Oct 11, 2006 By TSC Staff. Shares of Trimeris (TRMS - commentary - Cramer's Take) were slammed in late trading Wednesday after the company cut the sales forecast for its ... TheStreet.com - TheStreet.com (subscription) Roche says FUZEON combination treatment achieves undetectable … - Oct 5, 2006 ZURICH (AFX) - Roche Holdings AG said that new clinical studies have shown that 90-95 pct of treatment-experienced HIV patients who initiate therapy with ... Forbes Roche, Trimeris say anti-HIV drug Fuzeon reduces level of HIV virus... - Jul 23, 2007 ZURICH (Thomson Financial) - Roche Holdings AG and its US partner Trimeris Inc said interim results from a study with anti-HIV drug Fuzeon indicate that the ... Forbes Roche says FDA's approval of Tibotec HIV drug to boost Fuzeon potentia... - Jun 26, 2006 Fuzeon is jointly produced and marketed with US company Trimeris. Roche said that Prezista studies had shown that up to two-thirds of HIV patients had ... Forbes Study could revive Fuzeon: Trimeris drug treats HIV/AIDS. - Jul 20, 2007 Jul. 20--Growth of Fuzeon sales have slowed, and Trimeris, the Morrisville company that developed the HIV/AIDS drug with Swiss partner Roche, ... Free with registration - News & Observer - AccessMyLibrary.com Roche's Fuzeon/PI more than halves number of patients with detectable... - Dec 20, 2005 BASEL (AFX) - Roche Holding AG said new interim data on HIV treatment Fuzeon (enfuvirtide) boosted by protease inhibitor (PI) TMC114/r shows more than a ... Forbes New HIV treatments slash into sales of Trimeris' Fuzeon - Jul 21, 2008 Global sales of Trimeris' HIV drug, Fuzeon, dropped 38 percent in the second quarter, data released Monday say. Trimeris (Nasdaq: TRMS), based in Durham, ... Bizjournals.com Trimeris says sales of HIV drug Fuzeon fell 34 pct. in 1Q - Apr 16, 2008 MORRISVILLE, NC—Biotechnology company Trimeris Inc. said Wednesday that worldwide sales of its HIV treatment Fuzeon fell 34 percent during the first quarter ... Boston Globe Roche's Fuzeon plus Darunvir boost chances to reach undetectable... - Dec 15, 2006 BASEL (AFX) - Roche Holding AG said that according to the latest study data Tibotec's protease inhibitor Darunavir, used in combination with Roche's fusion ... Forbes Trimeris reports 20% increase in Fuzeon sales - Feb 6, 2007 Trimeris shares climbed nearly 3 percent in after-hours trading Tuesday after the Morrisville drugmaker said sales of HIV drug Fuzeon increased more than 20 ... Bizjournals.com Declining Fuzeon sales hurt Trimeris - Nov 7, 2008 Trimeris' earnings shrank in the third quarter as sales of Fuzeon, one of the few remaining assets of the troubled Durham company, continued to drop. ... News & Observer Trimeris loses less; Fuzeon demand up - Mar 11, 2005 DURHAM -- Trimeris narrowed its losses in the fourth quarter as demand increased for its Fuzeon HIV treatment. The company reported a $5.7 million loss ... Pay-Per-View - News & Observer - Factiva, from Dow Jones Novartis sues Trimeris over AIDS drug Fuzeon - Nov 27, 2007 Trimeris is the target of a patent infringement suit over its AIDS drug Fuzeon, the company said in a regulatory filing Tuesday. ... Bizjournals.com Fuzeon sales go up 31 percent. - Apr 26, 2006 Apr. 26--MORRISVILLE -- Sales of Fuzeon, Trimeris' HIV treatment, continued to increase in the first quarter, bolstering the company's projections that it ... Free with registration - News & Observer - AccessMyLibrary.com Trimeris falls after Roche deal change, exec departures - Mar 16, 2007 Shares of the company, which developed the HIV drug Fuzeon with Roche AG (ROG. ... Fuzeon, which is already marketed, also belongs to the class of anti-HIV ... Reuters Trimeris Reports Second Quarter 2006 FUZEON Sales Results - Jul 19, 2006 Trimeris, Inc. (NASDAQ: TRMS) today announced that net sales of FUZEON in the US and Canada for the second quarter 2006 were $31.1 million, an increase of ... Genetic Engineering News - Genetic Engineering News (press release) Morrisville, NC drug maker reports lower-than-expected losses. - Jul 21, 2005 The Morrisville drug maker is still losing money, and Fuzeon, the AIDS drug it ... Increases in Fuzeon sales, fueled by growth in Europe and Brazil, ... Free with registration - News & Observer - AccessMyLibrary.com Roche to suspend HIV research, seeing no advances - Jul 11, 2008 Roche said it would continue to support its molecular diagnostic tests and drugs already on the market, including the fusion-inhibitor Fuzeon. ... Reuters Newest HIV drugs should be used with FUZEON(R) - Jul 27, 2005 Data presented at IAS build a compelling case for FUZEON (enfuvirtide, formerly known as T-20) to be combined with the newest drugs to give patients facing ... i-newswire.com Trimeris shareholder asks company to explore sale - Aug 14, 2007 However, it is optimistic about Trimeris' currently-sold HIV drug Fuzeon, ... VX), which sells Fuzeon and books all its sales, was in a deal with Trimeris ... Reuters … Letter in Response to Application for Use of Fuzeon® with Needle... - Nov 24, 2005 Fuzeon is the first and only entry inhibitor available for the treatment of ... For this reason, Fuzeon is effective in treatment-experienced patients who ... DG News AIDS drug to boost Fuzeon: J&J to release new treatment. - Jul 1, 2006 Jul. 1--It's not just patients who are eagerly anticipating Johnson & Johnson's new AIDS treatment this month. Investors in Trimeris, a Morrisville drug ... Free with registration - News & Observer - AccessMyLibrary.com Trimeris says worldwide Q3 sales of HIV drug Fuzeon up 17 pct - Oct 15, 2007 Oct 15 (Reuters) - Trimeris Inc (TRMS.O) said worldwide third-quarter net sales of its HIV drug Fuzeon were $73.9 million, an increase of 17 percent from ... Reuters Roche and Trimeris Announce FDA Filing of FUZEON(R) sNDA for … - Jul 18, 2005 NUTLEY, NJ and MORRISVILLE, NC, July 18 /PRNewswire/ -- Roche and Trimeris today announced that the US Food and Drug Administration (FDA) has accepted the ... RedOrbit Trimeris Co-Founder, AIDS Pioneer Dani Bolognesi Launches New … - Mar 11, 2008 Fuzeon received FDA approval in 2003. Research done by Bolognesi and Dr. Tom Matthews, Trimeris' other co-founder, when they were at Duke led to Fuzeon, ... Local Tech Wire Today's Early Winners and Losers - Mar 10, 2006 The company said results were boosted by strong sales of Fuzeon, its HIV drug that it co-developed with Roche. Trimeris said it expects continued ... TheStreet.com - TheStreet.com (subscription) New HIV guidelines support use of FUZEON® + active boosted PI for … - Oct 14, 2005 Basel (CH), 14 October 2005. The importance of the drug FUZEON® (enfuvirtide) in the management of HIV has been officially recognised by the US Department ... eurekalert.org Roche to Stop Research Projects on Experimental HIV Treatments - Jul 14, 2008 Roche sells Viracept, Fuzeon and Invirase. HIV therapies brought in about 160 ... Fuzeon sales declined 38 percent to 46 million francs as patients switched ... Bloomberg … of Alternative Administration Options for Delivery of FUZEON(R). - Oct 3, 2007 We continue to review other options for administering FUZEON," said Michelle ... Administered via one 90 mg injection twice-daily, FUZEON is the first and ... $4.95 - Business Wire - ECNext New data presented at major AIDS meeting show Fuzeon plus an active … - Mar 1, 2005 Patients previously treated with three classes of antiretrovirals can achieve maximal viral suppression when starting a regimen of Fuzeon (enfuvirtide) in ... Free with registration - Asia Africa Intelligence Wire - AccessMyLibrary.com Trimeris announces strategic shift; to focus on FUZEON® profitability - Nov 15, 2006 MORRISVILLE, NC--(BUSINESS WIRE)--Trimeris, Inc. (NASDAQ: TRMS) announced that it will shift its strategic emphasis and reorganize to focus tightly on ... carolinanewswire.com Schering says its drug subdues AIDS virus - Feb 4, 2008 Before Selzentry won US approval in August 2007, the only so-called entry inhibitor available was Fuzeon. Fuzeon, made by Roche Holding AG and Trimeris Inc. ... Boston Globe Stocks in focus for Tuesday - MarketWatch - Oct 15, 2007 Trimeris Inc. said third-quarter sales of its Fuzeon anti-HIV drug rose 17% to ... Fuzeon sales in the US and Canada declined 9% to $30.6 million from $33.5 ... MarketWatch … Reports Third Quarter 2005 FUZEON Sales; Reschedules Earnings … - Oct 20, 2005 Trimeris, Inc. (NASDAQ: TRMS) today announced worldwide net sales of FUZEON were $48.9 million, up 43.1 percent from $34.2 million in the third quarter of ... businesswire.com Trimeris says Fuzeon sales fall 38% - Oct 20, 2008 Global sales of Trimeris' AIDS drug, Fuzeon, dropped by 38 percent in the third quarter, the company says. Durham-based Trimeris (Nasdaq: TRMS) says ... Triangle Business Journal New Trimeris CEO focuses on AIDS drugs - Nov 16, 2007 Though the firm remains profitable, sales of its only product, AIDS drug Fuzeon, have been well below expectations. Recently, the company's partner on ... Bizjournals.com New Treatment Guidelines Support Use of FUZEON(R) to Achieve … - Aug 14, 2006 Newly updated HIV/AIDS treatment guidelines, issued by the International AIDS Society-USA and published in this week's edition of the Journal of the ... RedOrbit … Shows Needle-Free Administration of FUZEON(R) Achieves Equivalent ... - Jan 27, 2005 NUTLEY, NJ and MORRISVILLE, NC, Jan. 27 /PRNewswire-FirstCall/ -- Data recently presented at HIV DART -- Frontiers in Drug Development for Antiretroviral ... RedOrbit Trimeris plans more layoffs, shifts Fuzeon responsibilities - Apr 2, 2007 Morrisville drug maker Trimeris plans to execute another round of layoffs and shift more of the responsibility for its only approved drug, HIV treatment ... Bizjournals.com Morrisville, NC-based firm studies next-generation AIDS drugs. - Jan 18, 2006 The Morrisville company that in 2003 began selling Fuzeon, the first and only ... Fuzeon must be injected twice a day, and reactions to those injections ... Free with registration - News & Observer - AccessMyLibrary.com FDA says Hoffmann-La Roche made misleading claims about HIV drug. - Jul 19, 2005 Fuzeon, which is injected, is the first in a new class of anti-HIV drugs called fusion ... Roche sold about $80 million of Fuzeon in the US last year. ... Free with registration - The Record - AccessMyLibrary.com Trimeris stock slips on lower drug sales - Jan 30, 2008 The company is developing a "next-generation" version of Fuzeon known as TRI-1144, but in December, Trimeris said it would end research and development ... Bizjournals.com Trimeris' AIDS drug posts higher sales - Oct 16, 2007 Sales of Fuzeon, Trimeris' AIDS drug, rebounded in the third quarter after ... Fuzeon, on which Trimeris splits profits with collaborative partner Roche, ... Bizjournals.com Google Shares Fall on Disappointing Report - Feb 1, 2006 Trimeris (TRMS ) Says 2005 worldwide net sales of Fuzeon were $208.2 million, ... It says Fuzeon sales in the US and Canada are expected to range from $140 ... BusinessWeek FUZEON Sales Growth Contributes to Improved 2004 Earnings Results … - Mar 10, 2005 MORRISVILLE, NC -- Trimeris, Inc. (NASDAQ: TRMS) today announced 2004 financial results indicating continued growth in worldwide sales of FUZEON(R), ... Free with registration - Business Wire - AccessMyLibrary.com … Integrase Inhibitor in Combination with FUZEON(R) Once-Daily... - Jul 17, 2007 The trial will also determine whether a novel, simplified FUZEON dosing ... FUZEON, co-developed by Roche and Trimeris , is the first and only fusion ... $4.95 - PR Newswire - ECNext Biotech jostles with pharma for slice of HIV market - Jan 5, 2006 Resistance is also a problem, and Fuzeon has been largely relegated to use in ... Clinical trials of entry inhibitors since Fuzeon have been dominated by ... Nature.com Trimeris Announces Special Dividend - Dec 9, 2008 FUZEON, approved in the US, Canada and European Union, is the first in a new class of anti-HIV drugs called fusion inhibitors. For more information about ... Bloomberg … Boosted Protease Inhibitor, TMC114, Works Better With FUZEON - Dec 21, 2005 This latest study provides further evidence that FUZEON now makes undetectable viral ... The 'FUZEON effect' has also been seen in other FUZEON/boosted PI ... Medical News Today - Medical News Today (press release) PRESS RELEASE: Trimeris Announces 2008 Strategic Plan - Dec 11, 2007 FUZEON, approved in the US, Canada and European Union, is the first in a new class of anti-HIV drugs called fusion inhibitors. For more information about ... FierceBiotech Fuzeon sales help Trimeris slash 2Q loss - Aug 9, 2006 Morrisville drug maker Trimeris on Tuesday reported a smaller second quarter loss in line with analysts' expectations. Trimeris' net loss of about $334000, ... Bizjournals.com Trimeris investor pushes sale - Feb 4, 2008 Trimeris was one of the Triangle's most promising drug-development companies, with a new AIDS drug called Fuzeon that analysts expected would be a huge ... News & Observer … boosted protease inhibitor, TMC114, works better with FUZEON - Dec 20, 2005 This latest study provides further evidence that FUZEON now makes undetectable viral ... The 'FUZEON effect' has also been seen in other FUZEON/boosted PI ... eurekalert.org Trimeris Reports First Quarter 2007 FUZEON(R) Sales Results - Apr 17, 2007 Trimeris, Inc. (NASDAQ: TRMS) today announced worldwide net sales of FUZEON for the first quarter of 2007 were $64.3 million, an increase of 16 percent from ... Genetic Engineering News - Genetic Engineering News (press release) New Data Show FUZEON(R) Continues to Provide Significant Immune … - Jun 26, 2006 NUTLEY, NJ & MORRISVILLE, NC -- A new analysis of the TORO studies presented in an oral session at the 15th International HIV Drug Resistance Workshop in ... Free with registration - Business Wire - AccessMyLibrary.com Trimeris to Release Third Quarter 2008 Financial Results on - Oct 31, 2008 FUZEON, approved in the US, Canada and European Union, is the first in a new class of anti-HIV drugs called fusion inhibitors. For more information about ... Bloomberg Trimeris reports 3Q 2005 Fuzeon sales; reschedules earnings … - Oct 18, 2005 Trimeris Inc announced worldwide net sales of Fuzeon were $48.9 M for 3Q ended Sep 2005 (+43.1% over $34.2 M in 3Q ended Sep 2004). Net sales of Fuzeon in ... Free with registration - Asia Africa Intelligence Wire - AccessMyLibrary.com Event Brief of Trimeris, Inc. Sales Conference Call - Final. - Oct 16, 2006 Management reported that 3Q06 FUZEON total global sales were $63m. 3Q06 FUZEON sales (US and Canada) were $33.6m. 3Q06 FUZEON net sales (Outside the US and ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Trimeris to shift focus to Fuzeon; plans job cuts. - Nov 14, 2006 SAN FRANCISCO (MarketWatch) -- Trimeris Inc. after Tuesday's closing bell said it plans to sharply reduce expenses to increase earnings from Fuzeon, ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Positive Pre-Clinical Data on Two New Investigational HIV Fusion … - Feb 9, 2006 Since its approval, FUZEON has increasingly become recognized as a ... Potency against this panel of FUZEON-sensitive viruses was up to seven times greater ... RedOrbit Swiss shares flat in thin morning trade ahead of US rate decision - Jun 26, 2006 ...approval of Tibotec Pharmaceuticals' HIV drug Prezista to result in potential new applications for its Fuzeon treatment as combination therapy. ... Forbes … Inhibitor Enables Potent New HIV Drug Combination with FUZEON(R) - Jun 23, 2006 ..."With the concurrent availability of FUZEON and darunavir/r, achieving undetectable ... It is important for clinicians to recognize the potency that FUZEON, ... Genetic Engineering News - Genetic Engineering News (press release) Trimeris, Roche To Market Needle-Free Device With Antiretroviral... - Oct 5, 2007 Fuzeon,a fusion inhibitor, is approved to treat HIV infection in ... About 10% of eligible US HIV-positivepatients were taking Fuzeon in 2005 ( Kaiser Daily ... emaxhealth.com Q1 2006 Trimeris, Inc. Earnings Conference Call - Final. - May 10, 2006 Second, strong FUZEON sales in the first quarter of this year reflect a steady growth in ... As noted in our earlier FUZEON sales call, the FUZEON effect, ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com … Letter in Response to Application for Use of FUZEON With Needle... - Nov 23, 2005 FUZEON is the first and only entry inhibitor available for the treatment of ... For this reason, FUZEON is effective in treatment-experienced patients who ... Free with registration - PR Newswire - AccessMyLibrary.com … With New Integrase Inhibitor Plus FUZEON And Boosted Protease … - Mar 6, 2007 Virtually all patients (98 percent) who received the investigational integrase inhibitor raltegravir, along with FUZEON ® (enfuvirtide) and an active ... Medical News Today - Medical News Today (press release) IAS: Needle-Less Injection System Makes Fuzeon Patient-Friendly - Jul 28, 2005 By Ed Susman,. RIO DE JANEIRO, Brazil, July 28 - An investigational needle-free gas-powered injection system simplifies the use of Fuzeon (enfuvirtide), ... MedPage Today Roche to cut 20% of Boulder workers - Oct 19, 2007 Roche markets Fuzeon for its developer, North Carolina-based Trimeris Inc. Roche ... Approved in 2003, Fuzeon is used in combination with other drugs. ... Rocky Mountain News Data on New Options to Improve FUZEON Self-Injection Presented at … - Jul 25, 2005 RIO DE JANEIRO, Brazil, July 25 /PRNewswire/ -- Researchers are evaluating two new methods for self-injecting FUZEON(R) (enfuvirtide) in an effort to ... $4.95 - PR Newswire - ECNext Roche developing next-generation Fuzeon. - Jan 17, 2006 WASHINGTON, Jan. 17 (UPI) -- Roche and Timeris, which currently market the only approved fusion inhibitor Fuzeon, are developing two next-generation fusion ... Free with registration - UPI Health Business - AccessMyLibrary.com … achieve undetectable viral load with Fuzeon and investigational... - Dec 19, 2005 Fuzeon, co-developed by Roche and Trimeris, is the first and only fusion ... Sixty-four percent of patients who received Fuzeon for the first time with ... Pay-Per-View - Company Reports - Factiva, from Dow Jones Trimeris to Release Fourth Quarter 2005 FUZEON Sales Results on … - Jan 31, 2006 MORRISVILLE, NC--(BUSINESS WIRE)--Jan. 26, 2006--Trimeris, Inc. (NASDAQ:TRMS) today announced that it will release FUZEON sales results for the fourth ... businesswire.com Darunavir With FUZEON Provides HIV Patients A Better Chance To … - Dec 19, 2006 The positive opinion by the European Committee for Medicinal Products for Human Use (CHMP) of Tibotec's boosted protease inhibitor darunavir is good news ... Medical News Today - Medical News Today (press release) Combined Isentress and Fuzeon cuts HIV levels in study.(Clinical... - Mar 12, 2007 Swiss drugmaker Roche says that nearly all of the patients treated with the investigational integrase inhibitor Isentress (raltegravir), being developed by ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Importance of the drug Fuzeon (enfuvirtide) in the management of HIV - Oct 20, 2005 New potent combinations make suppression of virus to undetectable levels more achievable for treatment-experienced HIV patients. ... News-Medical.net HIV drug may be just as effective without injections, study reports. - Jan 28, 2005 The drug, Fuzeon, was heralded as a revolutionary new weapon against HIV when it ... The study, which had 27 patients receiving Fuzeon for the first time, ... Free with registration - Herald Sun - AccessMyLibrary.com … Data Presented at Major AIDS Meeting Show FUZEON Plus an Active … - Mar 1, 2005 New Data Presented at Major AIDS Meeting Show FUZEON Plus an Active Protease Inhibitor Provides Maximal HIV Suppression in Treatment Experienced Patients. Pay-Per-View - PR Newswire - HighBeam Research … : Roche and Trimeris Announce FDA Filing of FUZEON(R) sNDA for … - Jul 18, 2005 Roche and Trimeris Announce FDA Filing of FUZEON(R) sNDA for Administration with a Needle-Free Injection Device. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research Trimeris stock soars on blockbuster 3Q - Nov 7, 2006 Company officials attributed the lucrative quarter to strong sales of HIV drug Fuzeon, which brought in $63 million during the 2006 third quarter. ... Bizjournals.com … HIV/AIDS Treatment Guidelines Support Use of FUZEON Plus an Active... - Oct 13, 2005 Updated HIV/AIDS Treatment Guidelines Support Use of FUZEON Plus an Active Boosted Protease Inhibitor to Achieve New Treatment Goal. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research Trimeris appoints Stephen R. Davis and Barry D. Quart, Pharm.D. to … - Jul 2, 2007 FUZEON, approved in the US, Canada and European Union, is the first in a new class of anti-HIV drugs called fusion inhibitors. For more information about ... carolinanewswire.com Event Brief of Q2 2007 Trimeris, Inc. Earnings Conference Call -... - Aug 9, 2007 This positive result was primarily driven by an increase in FUZEON sales and a decrease in ... Worldwide net sales of FUZEON for 2Q07 were $62m, an increase ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Fuzeon update.(Treatment News) | Article from HIV Treatment: ALERTS!... - Apr 1, 2005 Fuzeon update.(Treatment News) ... find HIV Treatment: ALERTS! articles. Changes have been made to the Fuzeon labeling to emphasize certain side effects of ... Pay-Per-View - HIV Treatment: ALERTS! - HighBeam Research Trimeris Reports Financial Results for the Fourth Quarter and Year... - Mar 13, 2008 Collaboration income decreased as a result of lower FUZEON(R) sales in North ... All sales of FUZEON are recorded by F. Hoffmann-La Roche Ltd. ("Roche"), ... Genetic Engineering News - Genetic Engineering News (press release) FUZEON Combined With New Investigational HIV Drug Results in … - May 10, 2006 Exciting new clinical data demonstrate that 90 to 95 percent of treatment-experienced HIV patients who initiate therapy with FUZEON(R) (enfuvirtide) and the ... presseportal.de … Announces First Quarter 2005 FUZEON Sales - Significant Worldwide ... - Apr 19, 2005 MORRISVILLE, NC -- Trimeris, Inc. (NASDAQ:TRMS) today announced worldwide net sales of FUZEON for the first quarter of 2005 of $42.5 million compared to net ... $4.95 - Business Wire - ECNext Article: The price of Fuzeon resistance.(12th Retrovirus Conference … - Apr 1, 2005 The price of Fuzeon resistance.(12th Retrovirus Conference HIGHLIGHTS)(Brief Article) ... find HIV Treatment: ALERTS! articles. As several research studies ... Pay-Per-View - HIV Treatment: ALERTS! - HighBeam Research … : Newest HIV Drugs Should be Used With FUZEON(R). - PR Newswire … - Jul 27, 2005 Newest HIV Drugs Should be Used With FUZEON(R). from PR Newswire Europe. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire Europe - HighBeam Research Phase Bioscience Replaces CEO with Former Trimeris President - Apr 11, 2007 Ellis helped develop the HIV drug Fuzeon while working at Trimeris. He also worked at Burroughs Wellcome where he was involved in virology research. ... Local Tech Wire New Weapon Against HIV? - Jun 16, 2006 One injectable drug by Roche and Trimeris, called Fuzeon, prevents the virus from entering cells, but the market for injections is always limited because ... Red Herring Event Brief of Q3 2006 Trimeris, Inc. Earnings Conference Call -... - Nov 7, 2006 Strong global sales of FUZEON, which grew by 29% over 3Q05. 2. Improvements in FUZEON COGS and favorable gross-to-net sales adjustments. ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com NH's Fuzeon Waiting List is One Patient Too Long - Jan 13, 2005 By Rebecca Kaufman on Thursday, January 13, 2005. Doctors and patients are excited about the new possibilities the drug offers people infected with HIV. ... NHPR Man accuses McDonald's of Aids prejudice - Jun 20, 2005 Then his doctor advised him to get involved with a clinical trial for the drug Fuzeon, which Rich credits with saving his life. ... Independent Online New anti-HIV drug will save lives, Aids foundation says - Aug 24, 2006 The Government's drug-buying agency Pharmac announced today it would start subsidising enfuvirtide (also known as fuzeon, or T20), from September 1. ... New Zealand Herald Former Trimeris exec takes Md. CEO position - Oct 29, 2007 Skolsky, who left Morrisville-based Trimeris in late 2006 amid disappointing sales of the company's AIDS drug Fuzeon, will become CEO at Gaithersburg, ... Bizjournals.com Roche and Trimeris report benefits of Fuzeon combo - Mar 2, 2005 New study data has shown that Roche and Trimeris' Fuzeon plus an active boosted protease inhibitor provides maximal HIV suppression in treatment-experienced ... Pay-Per-View - Datamonitor News and Comment - Factiva, from Dow Jones Newest HIV drugs should be given with Fuzeon, data indicates.(research... - Aug 1, 2005 Results unveiled at the International AIDS Society Conference in Rio de Janeiro, Brazil, support mounting evidence which suggests that Swiss drugmaker Roche ... $4.95 - Pharma Marketletter - ECNext Trimeris Reports Third Quarter 2007 FUZEON(R) Sales Results - Oct 15, 2007 Trimeris, Inc. (Nasdaq: TRMS) today announced worldwide net sales of FUZEON for the third quarter of 2007 were $73.9 million, an increase of 17 percent from ... Genetic Engineering News - Genetic Engineering News (press release) Event Brief of Q2 2005 Trimeris, Inc. Earnings Conference Call -... - Jul 19, 2005 Worldwide net sales of FUZEON were $53.9m, up 48% from $36.4m in 2Q04 and up 27% from 1Q05. 1. Net FUZEON sales in North America for 2Q05 were $25.2m, ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Support program helps Fuzeon patients - Oct 25, 2007 ...by Raymond J. Aguilera. Health care providers and consumers gathered in Oakland for a informational meeting last month sponsored by Roche Pharmaceuticals to ... Bay Area Reporter Brand Names/Synonyms: Fuzeon is also known by the following brand names and/or synonymsEnvelope polyprotein GP160 precursor [Contains: Exterior membrane glycoprotein;GP120; Transmembrane glycoprotein;GP41]; Fuzeon (Roche Pharmaceuticals) Drug Category: Fuzeon is categorized under the following by the FDA: Anti-HIV Agents Dosage Forms: Not Available Absorption: Not Available Interactions: Not Available Chemical IUPAC Name: YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |